应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CBPO 泰邦生物
休市中 04-04 16:00:00 EDT
119.99
+0.00
0.00%
最高
119.99
最低
119.99
成交量
0.00
今开
119.99
昨收
119.99
日振幅
0.00%
总市值
46.54亿
流通市值
15.65亿
总股本
3,879万
成交额
0.00
换手率
0.00%
流通股本
1,305万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
博雅生物:天坛生物、上海莱士、华兰生物和泰邦生物四家企业的采浆量全国占比超过50%
每日经济新闻 · 2021-12-17
博雅生物:天坛生物、上海莱士、华兰生物和泰邦生物四家企业的采浆量全国占比超过50%
2022年中国凝血因子行业竞争格局及市场份额分析 泰邦生物凝血因子产品签批发量最高
前瞻产业研究院 · 2021-12-02
2022年中国凝血因子行业竞争格局及市场份额分析 泰邦生物凝血因子产品签批发量最高
消息指泰邦生物考虑明年赴港上市 拟集资10亿美元 今年4月在纳交所退市
市场资讯 · 2021-11-26
消息指泰邦生物考虑明年赴港上市 拟集资10亿美元 今年4月在纳交所退市
【新股IPO】传泰邦生物考虑明年赴港上市
凤凰网港股 · 2021-11-25
【新股IPO】传泰邦生物考虑明年赴港上市
《新股消息》据报泰邦生物拟明年赴港上市 集资最多10亿美元
AAFN · 2021-11-25
《新股消息》据报泰邦生物拟明年赴港上市 集资最多10亿美元
泰邦生物考虑明年在香港IPO。(IFR)
新浪财经 · 2021-11-25
泰邦生物考虑明年在香港IPO。(IFR)
高瓴一季度美股持仓公布:中概股占主力位置 加仓企业服务赛道 百济神州成第一重仓股
格隆汇 · 2021-05-17
高瓴一季度美股持仓公布:中概股占主力位置 加仓企业服务赛道 百济神州成第一重仓股
泰邦生物完成私有化:买方团由大钲资本牵头 中信高瓴参与
雷递 · 2021-04-25
泰邦生物完成私有化:买方团由大钲资本牵头 中信高瓴参与
泰邦生物完成私有化!已停止纳斯达克市场交易
资本邦 · 2021-04-20
泰邦生物完成私有化!已停止纳斯达克市场交易
加载更多
公司概况
公司名称:
泰邦生物
所属市场:
NASDAQ
上市日期:
--
主营业务:
泰邦生物集团公司于1989年12月20日在开曼群岛注册成立。公司是中国领先的综合性血液制品生物制药集团企业。集团的核心业务包括血浆采集、血液生物制品的研发、生产和销售。泰邦产品线涵盖白蛋白、免疫球蛋白及凝血因子共三大类20多种不同规格的血液制品,及其他生物制药产品。此外,集团还有许多在研新产品,可以进一步地提升泰邦未来的增长。集团始终致力于新产品研发和新工艺探索,注重人才的引进与培养,建立了一支高素质的科研团队,具备专业而高效的研发能力,同时广泛拓展并与国内外研究机构合作,先后承担多项国家、省、市级科技攻关项目。集团总部位于北京,通过全资的贵州泰邦生物制品有限公司、控股的山东泰邦生物制品有限公司及参股的西安回天血液制品有限责任公司三家企业进行生产。三家生产企业各下设有精心选址、有效管理的单采血浆公司,提供生产血液制品所需要的原料血浆。泰邦集团建立了高效的销售渠道。产品目前直销至600多家医院和疾控中心,并致力于进一步提升终端市场的占有率。
发行价格:
--
{"stockData":{"symbol":"CBPO","market":"US","secType":"STK","nameCN":"泰邦生物","latestPrice":119.99,"timestamp":1743796800000,"preClose":119.99,"halted":0,"volume":0,"delay":0,"floatShares":13045258,"shares":38788096,"eps":3.82,"marketStatus":"休市中","change":0,"latestTime":"04-04 16:00:00 EDT","open":119.99,"high":119.99,"low":119.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.82,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1259730000000,"exchange":"NASDAQ","adjPreClose":119.99,"volumeRatio":0,"impliedVol":0.1666,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CBPO","defaultTab":"news","newsList":[{"id":"2192927467","title":"博雅生物:天坛生物、上海莱士、华兰生物和泰邦生物四家企业的采浆量全国占比超过50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2192927467","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2192927467?lang=zh_cn&edition=full","pubTime":"2021-12-17 16:25","pubTimestamp":1639729538,"startTime":"0","endTime":"0","summary":"博雅生物12月17日在投资者互动平台表示,近年来,大型血液制品公司通过兼并、收购的方式,使我国血液制品行业集中度得到大幅提升。目前已形成以天坛生物、上海莱士、华兰生物、泰邦生物等大型血液制品公司为行业龙头的局面。国内血液制品企业通过提高采浆量,扩大生产规模,加之企业间的兼并重组,行业逐步走向集中,天坛生物、上海莱士、华兰生物和泰邦生物四家企业的采浆量全国占比超过50%。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202112171628177a17509e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202112171628177a17509e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600161","002007","002252","CBPO","300294"],"gpt_icon":0},{"id":"2188594267","title":"2022年中国凝血因子行业竞争格局及市场份额分析 泰邦生物凝血因子产品签批发量最高","url":"https://stock-news.laohu8.com/highlight/detail?id=2188594267","media":"前瞻产业研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2188594267?lang=zh_cn&edition=full","pubTime":"2021-12-02 14:20","pubTimestamp":1638426000,"startTime":"0","endTime":"0","summary":"人凝血因子Ⅷ是我国凝血因子批签发量最大的细分产品,基本维持占比在40%左右。泰邦生物凝血因子产品签批发量最高整体来看凝血因子市场情况,批签发量前三位为泰邦生物、华兰生物和上海莱士。2020年其各自签发情况为:泰邦生物155万瓶,华兰生物131万瓶,上海莱士111万瓶。","market":"us","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202112021438227c5aef23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202112021438227c5aef23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBPO"],"gpt_icon":0},{"id":"2186604313","title":"消息指泰邦生物考虑明年赴港上市 拟集资10亿美元 今年4月在纳交所退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2186604313","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2186604313?lang=zh_cn&edition=full","pubTime":"2021-11-26 11:56","pubTimestamp":1637898992,"startTime":"0","endTime":"0","summary":" 中华网财经11月26日讯中华网财经了解到,据外电报道指,今年四月在纳斯达克交易所退市的泰邦生物,据报正考虑在明年赴港上市,目前已经与潜在的顾问机构进行初步商讨,计划集资10亿美元。 泰邦生物成立于2002年,是综合性血液制品和生物医药企业,其核心业务包括血浆采集、血液制品和生物制品的研发、生产和销售。 泰邦生物于2009年在纳斯达克交易所上市,于今年4月,以每股120美元完成私有化收购,总估值约为47.6亿美元。","market":"hk","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2021-11-26/doc-ikyamrmy5193133.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2021-11-26/doc-ikyamrmy5193133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["CBPO"],"gpt_icon":0},{"id":"2186940367","title":"【新股IPO】传泰邦生物考虑明年赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2186940367","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2186940367?lang=zh_cn&edition=full","pubTime":"2021-11-25 14:31","pubTimestamp":1637821902,"startTime":"0","endTime":"0","summary":"凤凰网港股|据悉,今年4月在纳斯达克交易所退市的泰邦生物考虑明年赴港上市,正与潜在顾问机构进行初步蹉商,计划集资高达10亿美元(折合约78亿港元)。以北京为基地的泰邦生物成立于2002年,并于2009年在纳斯达克上市。该公司是综合性血液制品和生物医药企业,其核心业务包括血浆采集、血液制品和生物制品的研发、生产和销售。目前拥有涵盖白蛋白、免疫球蛋白和凝血因子三大类、20多个品规的血液制品的产品线。","market":"us","thumbnail":"https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=9a41003d6918d5b1a72368a48292df1c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBPO"],"gpt_icon":0},{"id":"2186367660","title":"《新股消息》据报泰邦生物拟明年赴港上市 集资最多10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2186367660","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2186367660?lang=zh_cn&edition=full","pubTime":"2021-11-25 14:12","pubTimestamp":1637820749,"startTime":"0","endTime":"0","summary":"外电引述消息报道,今年4月从美国纳斯达克退市的泰邦生物,考虑明年赴港上市,拟集资最多10亿美元,公司已与潜在财务顾问进行初步讨论。根据泰邦官网资料,公司成立於2002年,是中国领先的综合性血液制品和生物医药企业,核心业务包括血液制品和生物制品的研发、生产和销售。(jl/t)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1145417&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["00388","CBPO"],"gpt_icon":0},{"id":"2186362430","title":"泰邦生物考虑明年在香港IPO。(IFR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2186362430","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2186362430?lang=zh_cn&edition=full","pubTime":"2021-11-25 12:24","pubTimestamp":1637814249,"startTime":"0","endTime":"0","summary":"泰邦生物考虑明年在香港IPO。(IFR)","market":"sh","thumbnail":"https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2021-11-25/doc-ikyamrmy4978895.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2021-11-25/doc-ikyamrmy4978895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["CBPO"],"gpt_icon":0},{"id":"2136995280","title":"高瓴一季度美股持仓公布:中概股占主力位置 加仓企业服务赛道 百济神州成第一重仓股","url":"https://stock-news.laohu8.com/highlight/detail?id=2136995280","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2136995280?lang=zh_cn&edition=full","pubTime":"2021-05-18 06:56","pubTimestamp":1621292162,"startTime":"0","endTime":"0","summary":"数据显示,高瓴在美股市场持有91家公司的股票,总市值为101亿美元,中概股依然占据强势地位,硬科技、医药医疗、消费仍旧是其重点投资行业。高瓴被投企业涂鸦智能在一季度完成美股上市,此次也出现在了13F名单中。截至一季度末,高瓴在美股持有万国数据314万股,市值排在高瓴美股持仓的第12位;同时,高瓴在一季度继续加仓了Salesforce 6.4万股,截至一季度末,Salesforce持有市值已经在高瓴美股持仓中排在第13位。","market":"us","thumbnail":"https://static.tigerbbs.com/e62f8ab97654b9d4f235a7b85cd8647e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e62f8ab97654b9d4f235a7b85cd8647e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/news/detail.html?id=524421","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["IQ","QNETCN","JD","06160","TTTN","CBPO","PDD","BGNE"],"gpt_icon":0},{"id":"2130393509","title":"泰邦生物完成私有化:买方团由大钲资本牵头 中信高瓴参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2130393509","media":"雷递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2130393509?lang=zh_cn&edition=full","pubTime":"2021-04-25 18:46","pubTimestamp":1619347560,"startTime":"0","endTime":"0","summary":"2020年11月19日,泰邦生物宣布与大钲资本牵头的买方团达成收购协议。2021年3月1日,泰邦生物特别股东大会批准了该项交易。泰邦生物私有化交易背后的投资机构团队可谓豪华。分析人士称,泰邦生物的私有化计划可能与中概医药股在国外资本市场待遇遇冷,长期保持在低估值的区域有关。泰邦生物管理层在财报会上表示,对中长期的中国血浆业务增长前景持乐观态度。","market":"fut","thumbnail":"https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5MzQ5NjIyMQ==&mid=2661508751&idx=8&sn=d098846d2fea8360931d350d878ae16a&chksm=bdc1eb7d8ab6626b48eb721eed2bb64b95560f2dfc51fbf7db9a690d85049b725b1f53ea7c64&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["CBPO"],"gpt_icon":0},{"id":"2129687819","title":"泰邦生物完成私有化!已停止纳斯达克市场交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2129687819","media":"资本邦","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2129687819?lang=zh_cn&edition=full","pubTime":"2021-04-21 00:00","pubTimestamp":1618934400,"startTime":"0","endTime":"0","summary":"泰邦生物与CBPO Holdings Limited(母公司)的全资子公司CBPO Group Limited(合并子公司)完成合并,将不再是上市公司。","market":"us","thumbnail":"https://www.chinaipo.com/data/upload/2021/0421/11/607fa1bddeccc_300_200.jpg","type":0,"news_type":0,"thumbnails":["https://www.chinaipo.com/data/upload/2021/0421/11/607fa1bddeccc_300_200.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chinaipo.com/news/147254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"chinaipo_stock","symbols":["03086","QID","QLD","PSQ","QQQ","TQQQ","NQmain","CBPO","SQQQ","MNQmain",".IXIC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinabiologic.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1334},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1182},{"period":"1year","weight":-0.0152},{"period":"ytd","weight":-0.1379}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"泰邦生物集团公司于1989年12月20日在开曼群岛注册成立。公司是中国领先的综合性血液制品生物制药集团企业。集团的核心业务包括血浆采集、血液生物制品的研发、生产和销售。泰邦产品线涵盖白蛋白、免疫球蛋白及凝血因子共三大类20多种不同规格的血液制品,及其他生物制药产品。此外,集团还有许多在研新产品,可以进一步地提升泰邦未来的增长。集团始终致力于新产品研发和新工艺探索,注重人才的引进与培养,建立了一支高素质的科研团队,具备专业而高效的研发能力,同时广泛拓展并与国内外研究机构合作,先后承担多项国家、省、市级科技攻关项目。集团总部位于北京,通过全资的贵州泰邦生物制品有限公司、控股的山东泰邦生物制品有限公司及参股的西安回天血液制品有限责任公司三家企业进行生产。三家生产企业各下设有精心选址、有效管理的单采血浆公司,提供生产血液制品所需要的原料血浆。泰邦集团建立了高效的销售渠道。产品目前直销至600多家医院和疾控中心,并致力于进一步提升终端市场的占有率。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":-0.006394},{"month":2,"riseRate":0.428571,"avgChangeRate":0.018411},{"month":3,"riseRate":0.5,"avgChangeRate":0.050655},{"month":4,"riseRate":0.533333,"avgChangeRate":0.021361},{"month":5,"riseRate":0.5,"avgChangeRate":0.020545},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.026211},{"month":7,"riseRate":0.692308,"avgChangeRate":0.037753},{"month":8,"riseRate":0.153846,"avgChangeRate":-0.059739},{"month":9,"riseRate":0.384615,"avgChangeRate":0.013678},{"month":10,"riseRate":0.384615,"avgChangeRate":0.014188},{"month":11,"riseRate":0.846154,"avgChangeRate":0.100639},{"month":12,"riseRate":0.307692,"avgChangeRate":0.055772}],"exchange":"NASDAQ","name":"泰邦生物","nameEN":"China Biologic"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰邦生物(CBPO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰邦生物(CBPO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰邦生物,CBPO,泰邦生物股票,泰邦生物股票老虎,泰邦生物股票老虎国际,泰邦生物行情,泰邦生物股票行情,泰邦生物股价,泰邦生物股市,泰邦生物股票价格,泰邦生物股票交易,泰邦生物股票购买,泰邦生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰邦生物(CBPO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰邦生物(CBPO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}